Enric Carcereny-Costa - Publications

Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 06, 2024

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

Journal: ESMO open

Published: August 15, 2023

Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancer.

Journal: Journal of biomedical informatics

Published: December 15, 2022

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.

Journal: JTO clinical and research reports

Published: October 05, 2020

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 08, 2019

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: September 29, 2019

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 05, 2018

Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 22, 2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 14, 2017

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.

Journal: Cancer treatment reviews

Published: February 21, 2014